Baxter's shares rose 1.8% following a first quarter report that met expectations, with organic sales declining slightly but partially offset by growth in Advanced Surgery and ongoing innovation efforts. Despite margin pressures and challenging comps, the market reaction was modestly positive, reflecting cautious optimism on the company’s turnaround progress.

• Reported sales increased 3% year-over-year to $2.7 billion, but organic sales declined 1%, reflecting underlying demand softness.
• Adjusted EPS fell to $0.36 from $0.55 a year ago, pressured by tariff impacts, higher manufacturing costs, and unfavorable prior year comparables.
• Advanced Surgery segment delivered strong order growth and expanded 10% in the quarter, supporting growth outlook.
• Management highlighted progress on addressing infusion pump hardware and software issues, with ongoing regulatory coordination and mitigations in place.
• Innovation efforts include new product launches with AI enhancements and digital connectivity solutions aimed at improving clinical outcomes and operational efficiency.